B. J. Van-den-eynde and P. T. Van-der-bruggen, Cell-defined tumor antigens, Curr. Opin. Immunol, vol.9, pp.684-693, 1997.

S. A. Rosenberg, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Imunol. Today, vol.18, pp.175-182, 1997.

B. T. Rouse, H. Wagner, and A. W. Harris, In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes, J. Immunol, vol.108, pp.1353-1361, 1972.

C. J. Melief and W. M. Kast, T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes, Immunol. Rev, vol.145, pp.167-177, 1995.

M. A. Alexander-miller, G. R. Leggatt, and J. A. Berzofsky, Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy, Proc. Natl. Acad. Sci. USA, vol.93, pp.4102-4107, 1996.

D. E. Speiser, R. Miranda, A. Zakarian, M. N. Bachmann, K. Mc-kall-faienza et al., Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy, J. Exp. Med, vol.186, pp.645-653, 1997.

M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang et al., Successful adoptive immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-? and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes, J. Immunol, vol.160, pp.334-344, 1998.

S. R. Riddell, K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha et al., Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, Science (Washington DC), vol.257, pp.238-241, 1992.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin et al., Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes, Nat. Med, vol.2, pp.551-555, 1996.

T. Boon and L. Old, J. Cancer tumor antigens. Curr. Opin. Immunol, vol.9, pp.681-683, 1997.

E. Celis, V. Tsai, C. Crimi, R. Demars, P. A. Wentworth et al., Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes, Proc. Natl. Acad. Sci. USA, vol.91, pp.2105-2109, 1994.

P. Van-der-bruggen, J. Bastin, T. Gajewski, P. G. Coulie, P. Boel et al., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Eur. J. Immunol, vol.24, pp.3038-3043, 1994.

M. J. Visseren, A. Van-elsas, E. I. Van-der-voort, M. E. Ressing, W. M. Kast et al., CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells, J. Immunol, vol.154, pp.3991-3998, 1995.

L. Rivoltini, Y. Kawakami, K. Sakaguchi, S. Scouthwood, A. Sette et al., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1, J. Immunol, vol.154, pp.2257-2265, 1995.

V. Tsai, S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami et al., Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells, J. Immunol, vol.158, pp.1796-1802, 1997.

N. Gervois, Y. Guilloux, E. Diez, and F. Jotereau, Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions, J. Exp. Med, vol.183, pp.2403-2407, 1996.

P. R. Dunbar, J. L. Chen, D. Chao, N. Rust, H. Teisserenc et al., Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma, J. Immunol, vol.162, pp.6959-6962, 1999.

C. Yee, P. A. Savage, P. P. Lee, M. M. Davis, and P. Greenberg, Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers, J. Immunol, vol.162, pp.2227-2234, 1999.

J. F. Fonteneau, E. Le-drean, S. Le-guiner, N. Gervois, E. Diez et al., Heterogeneity of biologic responses of melanomaspecific CTL, J. Immunol, vol.159, pp.2831-2839, 1997.

S. Valitutti, S. Muller, M. Dessing, and A. Lanzavecchia, Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy, J. Exp. Med, vol.183, pp.1917-1921, 1996.

N. Gervois, F. Heuzé, E. Diez, and F. Jotereau, Selective expansion of a specific anti-tumor CD8? cytotoxic T lymphocyte clone in a bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements, Eur. J. Immunol, vol.20, pp.825-831, 1990.

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by flow cytometry, J. Immunol. Methods, vol.159, pp.197-207, 1993.

F. Jotereau, M. C. Pandolfino, D. Boudart, E. Diez, B. Dreno et al., High fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J. Immunother, vol.10, pp.405-411, 1991.

N. Labarrière, E. Diez, M. C. Pandolfino, C. Viret, Y. Guilloux et al., Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription, J. Immunol, vol.158, pp.1238-1245, 1997.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, pp.1750-1758, 1998.

M. H. Tessier, M. C. Pandolfino, F. Jotereau, D. Boudart, P. Litoux et al., Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma, Eur. J. Cancer, vol.4, pp.735-736, 1996.

M. J. Pittet, D. Valmori, P. R. Dunbar, D. E. Speiser, D. Lienard et al., Generation of MelanA/MART-1-specific CD8? cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro, 28. Ostankovitch, vol.190, pp.987-994, 1997.

M. A. Alexander-miller, M. A. Derby, A. Sarin, P. A. Henkart, and J. A. Berzofsky, Supraoptimal peptide-major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor ? receptor II-mediated apoptosis of cytotoxic T lymphocytes, J. Exp. Med, vol.188, pp.1391-1399, 1998.

L. Guiner, S. Le-drean, ;. E. Labarriere, N. Fonteneau, J. F. Viret et al., LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal, Eur. J. Immunol, vol.28, pp.1322-1331, 1998.

F. A. Harding, J. G. Mc-arthur, J. A. Gross, D. H. Raulet, A. et al., CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature (Lond.), vol.356, pp.607-609, 1992.

J. M. Green, P. J. Noel, A. I. Sperling, T. L. Walunas, G. S. Gray et al., Absence of B7-dependent responses in CD28-deficient mice, Immunity, vol.1, pp.501-508, 1994.

Z. Cai and J. Sprent, Influence of antigen dose and costimulation on the primary response of CD8? T cells in vitro, J. Exp. Med, vol.183, pp.2247-2257, 1996.

A. B. Bakker, G. Marland, A. J. De-boer, R. J. Huijbens, E. H. Danen et al., Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro, Cancer Res, vol.55, pp.5330-5334, 1995.

A. Mehta-damani, S. Markowicz, and E. G. Engleman, Generation of antigen-specific CD8? CTLs from naive precursors, J. Immunol, vol.153, pp.996-1003, 1994.

E. J. Stevens, L. Jacknin, P. F. Robbins, Y. Kawakami, M. El-gamil et al., Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines, J. Immunol, vol.154, pp.762-777, 1995.